Table 1.
Baseline characteristics by quartile of sCD14
| Full cohort (n = 5,380) | Quartile 1 (n = 1,250) | Quartile 2 (n = 1,249) | Quartile 3 (n = 1,250) | Quartile 4 (n = 1,250) | P for trend | |
|---|---|---|---|---|---|---|
| sCD14, ng/mL | 1,593 (1,399, 1,823) | 1,270 (1,187, 1,339) | 1,497 (1,450, 1,546) | 1,696 (1,649, 1,757) | 2,000 (1,888, 2,196) | <0.001 |
| Age, years | 72 (68, 76) | 71 (68, 75) | 71 (68, 75) | 72 (68, 76) | 73 (69, 78) | <0.001 |
| Men, n (%) | 2,245 (41.7) | 659 (52.7) | 578 (46.3) | 451 (36.1) | 396 (31.7) | <0.001 |
| Black, n (%) | 769 (14.3) | 301 (24.1) | 154 (12.3) | 121 (9.7) | 108 (8.6) | <0.001 |
| BMI, kg/m2 | 26.0 (23.4, 28.9) | 26.3 (24.0, 29.3) | 26.1 (23.6, 29.1) | 25.8 (23.3, 28.8) | 25.3 (22.7, 28.2) | <0.001 |
| Systolic blood pressure, mmHg | 134 (121, 149) | 133 (120, 147) | 134 (121, 150) | 134 (121, 150) | 134 (121, 151) | 0.025 |
| Antihypertensive medication, n (%) | 2,451 (45.6) | 511 (40.9) | 546 (43.8) | 588 (47.1) | 632 (50.6) | <0.001 |
| Smoking, n (%) | ||||||
| Never | 2,505 (46.6) | 584 (46.9) | 576 (46.2) | 558 (44.6) | 601 (48.1) | 0.741 |
| Past | 2,221 (41.3) | 545 (43.7) | 532 (42.6) | 521 (41.7) | 464 (37.1) | <0.001 |
| Current | 648 (12.1) | 117 (9.4) | 139 (11.2) | 171 (13.7) | 185 (14.8) | <0.001 |
| Heavy alcohol use, n (%) | 509 (9.5) | 89 (7.1) | 118 (9.5) | 143 (11.5) | 126 (10.1) | 0.003 |
| Physical activity, kilocalories/week | 1,081 (395, 2,356) | 1,134 (442, 2,416) | 1,179 (444, 2,446) | 1,115 (428, 2,401) | 901 (271, 2,116) | <0.001 |
| Estrogen use, n (%)* | 389 (12.4) | 138 (23.4) | 86 (12.8) | 80 (10.0) | 61 (7.2) | <0.001 |
| LDL cholesterol, mg/dL | 129 (107, 152) | 125 (104, 147) | 129 (109, 151) | 131 (109, 154) | 130 (106, 158) | <0.001 |
| HDL cholesterol, mg/dL | 52 (44, 64) | 52 (43, 64) | 52 (44, 63) | 53 (44, 64) | 52 (44, 65) | 0.525 |
| Triglycerides, mg/dL | 121 (93, 164) | 117 (91, 164) | 125 (96, 163) | 120 (94, 163) | 122 (91, 169) | 0.045 |
| Statin, n (%) | 111 (2.1) | 30 (2.4) | 36 (2.9) | 22 (1.8) | 20 (1.6) | 0.056 |
| Oral corticosteroid, n (%) | 114 (2.1) | 18 (1.4) | 21 (1.7) | 28 (2.2) | 37 (3.0) | 0.005 |
| NSAID, n (%) | 686 (12.8) | 159 (12.7) | 129 (10.3) | 173 (13.9) | 167 (13.4) | 0.194 |
| Prevalent ASCVD, n (%) | 1,189 (22.1) | 248 (19.8) | 261 (20.9) | 266 (21.3) | 313 (25.0) | 0.002 |
| Prevalent HF, n (%) | 222 (4.1) | 32 (2.6) | 49 (3.9) | 42 (3.4) | 74 (5.9) | <0.001 |
| eGFR, mL/min/1.73 m2 | 64.4 (53.5, 75.8) | 67.4 (57.4, 76.9) | 66.1 (56.1, 76.3) | 63.4 (52.9, 75.2) | 59.6 (47.3, 73.7) | <0.001 |
| CRP, mg/L | 2.5 (1.2, 4.5) | 1.9 (0.9, 3.5) | 2.2 (1.2, 3.9) | 2.6 (1.4, 4.5) | 3.2 (1.6, 7.7) | <0.001 |
| IL-6, pg/mL | 1.7 (1.1, 2.5) | 1.5 (1.0, 2.2) | 1.6 (1.1, 2.3) | 1.7 (1.2, 2.6) | 1.9 (1.3, 3.1) | <0.001 |
| WBC count, ×1,000/mm3 | 6.0 (5.0, 7.1) | 5.7 (4.9, 6.8) | 6.0 (5.1, 7.1) | 6.0 (5.0, 7.1) | 6.2 (5.2, 7.6) | <0.001 |
| Baseline glucose, mg/dL | 100 (94, 109) | 99 (93, 108) | 101 (94, 109) | 100 (94, 108) | 99 (93, 109) | 0.019 |
| Baseline insulin, IU/mL | 12 (9, 17) | 12 (9, 17) | 12 (9, 17) | 12 (9, 16) | 12 (9, 17) | 0.125 |
| QUICKI | 0.32 (0.31, 0.34) | 0.32 (0.29, 0.34) | 0.32 (0.31, 0.34) | 0.32 (0.31, 0.34) | 0.32 (0.31, 0.34) | 0.255 |
| HOMA2IR | 1.62 (1.21, 2.24) | 1.61 (1.20, 2.24) | 1.62 (1.22, 2.28) | 1.61 (1.23, 2.18) | 1.62 (1.21, 2.25) | 0.161 |
Data are median (interquartile range) for continuous variables unless otherwise indicated; 25th, 50th, and 75th percentiles of sCD14 are 1,399, 1,593, and 1,823, respectively. NSAID, nonsteroidal anti-inflammatory drug.
*
Only among women.